Alogliptin

• Description:

  Alogliptin (SYR-322 free base) is a potent, selective and orally active inhibitor of DPP-4 with an IC50 of [1][2][3].

• Product Name Alternative:

  SYR-322 (free base)

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Dipeptidyl Peptidase; Ferroptosis

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Metabolic Enzyme/Protease

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Metabolic Disease; Inflammation/Immunology; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/alogliptin.html

• Purity:

  99.93

• Solubility:

  DMSO : 100 mg/mL (ultrasonic) |H2O : 10 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  O=C(C=C(N1C[C@H](N)CCC1)N(C2=O)CC3=C(C#N)C=CC=C3)N2C

• Molecular Formula:

  C18H21N5O2

• Molecular Weight:

  339.40

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Feng J, et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem. 2007 May 17;50 (10) :2297-300.|[2]Ta NN, et al. DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. Atherosclerosis. 2010 Dec;213 (2) :429-35.|[3]Asakawa T, et al. A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure. Life Sci. 2009 Jul 17;85 (3-4) :122-6.|[4]Moritoh Y, et al. The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice. Eur J Pharmacol. 2009 Jan 14;602 (2-3) :448-54.|[5]Hao FL, et, al. The neurovascular protective effect of alogliptin in murine MCAO model and brain endothelial cells. Biomed Pharmacother. 2019 Jan;109:181-187.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  DPP-4

• Citation 01:

  Research Square Preprint. 2025 Jan 08.|Sci Rep. 2019 Dec 2;9 (1) :18094.|Sci Signal. 2023 Jan 17;16 (768) :eabh1083.|Biochem Biophys Res Commun. 2019 Apr 2;511 (2) :387-393. |Biol Chem. 2023 Jan 12;404 (6) :633-643.|Chromatography. 2015,36 (1) :19-24.

• CAS Number:

  850649-61-5